Tags

Type your tag names separated by a space and hit enter

Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Pharmacotherapy 2007; 27(5):633-8P

Abstract

STUDY OBJECTIVES

To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio.

DESIGN

Prospective, open-label trial.

SETTING

University-affiliated cardiology clinic.

SUBJECTS

Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects.

INTERVENTION

All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks.

MEASUREMENTS AND MAIN RESULTS

For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean +/- SD baseline AA:EPA ratios were 39.6 +/- 19.0 in healthy subjects and 23.7 +/- 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 +/- 4.2 in healthy subjects and 10.3 +/- 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 +/- 3.2 in healthy subjects and 4.9 +/- 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day).

CONCLUSION

Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.

Authors+Show Affiliations

Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska 68178, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

17461697

Citation

Burns, Tammy, et al. "Effect of Omega-3 Fatty Acid Supplementation On the Arachidonic Acid:eicosapentaenoic Acid Ratio." Pharmacotherapy, vol. 27, no. 5, 2007, pp. 633-8.
Burns T, Maciejewski SR, Hamilton WR, et al. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy. 2007;27(5):633-8.
Burns, T., Maciejewski, S. R., Hamilton, W. R., Zheng, M., Mooss, A. N., & Hilleman, D. E. (2007). Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy, 27(5), pp. 633-8.
Burns T, et al. Effect of Omega-3 Fatty Acid Supplementation On the Arachidonic Acid:eicosapentaenoic Acid Ratio. Pharmacotherapy. 2007;27(5):633-8. PubMed PMID: 17461697.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. AU - Burns,Tammy, AU - Maciejewski,Stephanie R, AU - Hamilton,William R, AU - Zheng,Margaret, AU - Mooss,Aryan N, AU - Hilleman,Daniel E, PY - 2007/4/28/pubmed PY - 2007/6/27/medline PY - 2007/4/28/entrez SP - 633 EP - 8 JF - Pharmacotherapy JO - Pharmacotherapy VL - 27 IS - 5 N2 - STUDY OBJECTIVES: To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. DESIGN: Prospective, open-label trial. SETTING: University-affiliated cardiology clinic. SUBJECTS: Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. INTERVENTION: All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. MEASUREMENTS AND MAIN RESULTS: For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean +/- SD baseline AA:EPA ratios were 39.6 +/- 19.0 in healthy subjects and 23.7 +/- 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 +/- 4.2 in healthy subjects and 10.3 +/- 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 +/- 3.2 in healthy subjects and 4.9 +/- 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). CONCLUSION: Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/17461697/Effect_of_omega_3_fatty_acid_supplementation_on_the_arachidonic_acid:eicosapentaenoic_acid_ratio_ L2 - https://doi.org/10.1592/phco.27.5.633 DB - PRIME DP - Unbound Medicine ER -